At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
afatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Afatinib in Patients With Advanced NSCLC Harboring HER2 Mutations, Previously Treated With Chemotherapy
In Brief
A Phase 2 clinical trial evaluating afatinib and paclitaxel for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 18 participants across 9 sites in 2 countries.
Detailed Summary
to investigate effectiveness and safety of afatinib in the advanced NSCLC patients with HER2 mutations, previously treated with 1 or 2 chemotherapy regimens
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesChina, Malaysia
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartMar 2016
Primary CompletionJul 2018
TodayJul 2026
First PostedNov 5, 2015
Enrollment StartMar 18, 2016
Primary CompletionJul 22, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.7 years ago
Interventions
afatinibdrug
paclitaxeldrug